Participants 50 82 4
patients with advanced melanoma:
Participants 498 672 7
We designed a randomized phase II study to evaluate and compare the activity and safety profile of the combination versus single-agent TMZ in patients with advanced melanoma.
Participants 673 767 6
PATIENTS AND METHODS From January 2000 to April 2002, 132 patients were enrolled on the study.
Participants 768 842 3
Patient and tumor characteristics were well balanced between the two arms.
Participants 843 890 5
Patients with cerebral metastases were included
Participants 1054 1182 3
RESULTS Tumor responses (complete and partial responses) were seen in 16 patients (26%) in arm A and 19 patients (29%) in arm B.
